Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. |
| |
| Authors: | C F Barbas rd E Bj?rling F Chiodi N Dunlop D Cababa T M Jones S L Zebedee M A Persson P L Nara E Norrby et al. |
| |
| Affiliation: | Department of Molecular Biology, Scripps Research Institute, La Jolla, CA 92037. |
| |
| Abstract: | A panel of 20 recombinant Fab fragments reactive with the surface glycoprotein gp120 of human type 1 immunodeficiency virus (HIV-1) were examined for their ability to neutralize MN and IIIB strains of the virus. Neutralization was determined as the ability of the Fab fragments to inhibit infection as measured in both a p24 ELISA and a syncytium-formation assay. One group of closely sequence-related Fab fragments was found to neutralize virus in both assays with a 50% neutralization titer at approximately 1 micrograms/ml. Another Fab neutralized in the p24 ELISA but not in the syncytium assay. The other Fab fragments showed weak or no neutralizing ability. The results imply that virion aggregation or crosslinking of gp120 molecules on the virion surface is not an absolute requirement for HIV-1 neutralization. Further, all of the Fab fragments were shown to be competitive with soluble CD4 for binding to gp120 and yet few neutralized the virus effectively, implying that the mechanism of neutralization in this case may not involve receptor blocking. The observation of a preponderance of high-affinity Fab fragments with poor or no neutralizing ability could have implications for vaccine strategies. |
| |
| Keywords: | |
|
|
